{
    "clinical_study": {
        "@rank": "33363", 
        "arm_group": [
            {
                "arm_group_label": "Multiple Dose: Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 4", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Relative Bioavilability: Cohort 1", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety, tolerability and PK of repeated doses of PF-06305591 will be evaluated in young\n      healthy volunteers toghether with food effect on relative bioavailability of solid\n      formulation after single dose."
        }, 
        "brief_title": "Safety and Tolerability Study of Multiple Doses of PF-06305591", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female subjects of non childbearing potential, between the ages of 21\n             and 55 years, inclusive.  Healthy is defined as no clinically relevant abnormalities\n             identified by a detailed medical history, full physical examination, including blood\n             pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776619", 
            "org_study_id": "B5281002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Multiple Dose: Cohort 1", 
                "description": "14 day repeated 20mg BID doses", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 1", 
                "description": "14 day repeated BID doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 2", 
                "description": "14 day repeated 80mg BID doses", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 2", 
                "description": "14 day repeated BID doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 3", 
                "description": "14 day repeated 40mg BID doses", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 3", 
                "description": "14 day repeated BID doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Multiple Dose: Cohort 4", 
                "description": "14 day repeated BID doses", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Relative Bioavilability: Cohort 1", 
                "description": "relative bioavailability tablet vs. solution and food effect at  50mg dose", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "tolerability", 
            "PK"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5281002&StudyName=Safety%20and%20Tolerability%20Study%20of%20Multiple%20Doses%20of%20PF-06305591"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Double Blind (3rd Party Open) Randomized, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of Repeat Doses PF-06305591 Combined With a Cross-over Relative Bioavailability and Food Effect Evaluation After Single Dose of PF-06305591 in Healthy Young Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium : Commission d'Ethique Biom\u00e9dicale Hospitalo-Facultaire", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.", 
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "time_frame": "14 days"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time interval. It is used to characterize drug absorption.", 
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776619"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}